Overview

Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients. This is a 2nd bridging study to investigate the efficacy and safety of KI1001(Circadin®) in Korean patients.
Phase:
Phase 3
Details
Lead Sponsor:
Kuhnil Pharmaceutical Co., Ltd.
Collaborator:
Neurim Pharmaceuticals Ltd.
Treatments:
Melatonin